These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 12407677)

  • 1. Regression analysis based on pairwise ordering of patients' clinical histories.
    Follmann DA
    Stat Med; 2002 Nov; 21(22):3353-67. PubMed ID: 12407677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited.
    Parker AB; Yusuf S; Naylor CD
    Am Heart J; 2002 Dec; 144(6):941-7. PubMed ID: 12486418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction.
    Alsheikh-Ali AA; Wang PJ; Rand W; Konstam MA; Homoud MK; Link MS; Estes NA; Salem DN; Al-Ahmad AM
    Am Heart J; 2004 Jun; 147(6):1061-5. PubMed ID: 15199356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
    Vermes E; Tardif JC; Bourassa MG; Racine N; Levesque S; White M; Guerra PG; Ducharme A
    Circulation; 2003 Jun; 107(23):2926-31. PubMed ID: 12771010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
    Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Aguilar D; Solomon SD; Køber L; Rouleau JL; Skali H; McMurray JJ; Francis GS; Henis M; O'Connor CM; Diaz R; Belenkov YN; Varshavsky S; Leimberger JD; Velazquez EJ; Califf RM; Pfeffer MA
    Circulation; 2004 Sep; 110(12):1572-8. PubMed ID: 15364810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
    de Denus S; Tardif JC; White M; Bourassa MG; Racine N; Levesque S; Ducharme A
    Am Heart J; 2006 Oct; 152(4):705-12. PubMed ID: 16996842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
    Ferrari R;
    Arch Intern Med; 2006 Mar; 166(6):659-66. PubMed ID: 16567606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C; Cosentino E; De Sanctis D
    Ital Heart J Suppl; 2005 Dec; 6(12):769-79. PubMed ID: 16444921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
    Ishani A; Weinhandl E; Zhao Z; Gilbertson DT; Collins AJ; Yusuf S; Herzog CA
    J Am Coll Cardiol; 2005 Feb; 45(3):391-9. PubMed ID: 15680718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of angiotensin converting enzyme inhibitors on remodeling in clinical trials.
    Greenberg BH
    J Card Fail; 2002 Dec; 8(6 Suppl):S486-90. PubMed ID: 12555162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).
    Kjøller-Hansen L; Steffensen R; Grande P
    Am Heart J; 2004 Sep; 148(3):475-80. PubMed ID: 15389235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO; Kashani A; Ko DK; Francis G; Krumholz HM
    Arch Intern Med; 2007 Oct; 167(18):1930-6. PubMed ID: 17923591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.